A5037939650- Pharmacogenetics and Drug Metabolism
- Pharmaceutical studies and practices
- Computational Drug Discovery Methods
- Antibiotics Pharmacokinetics and Efficacy
- Statistical Methods in Clinical Trials
- Analytical Methods in Pharmaceuticals
- Biosimilars and Bioanalytical Methods
- Monoclonal and Polyclonal Antibodies Research
- Metabolomics and Mass Spectrometry Studies
- Pharmacological Effects and Toxicity Studies
- Protein purification and stability
- Drug Transport and Resistance Mechanisms
- CAR-T cell therapy research
- Epilepsy research and treatment
- Platelet Disorders and Treatments
- Malaria Research and Control
- Pharmacological Effects and Assays
- Physiological and biochemical adaptations
- Cholinesterase and Neurodegenerative Diseases
- Receptor Mechanisms and Signaling
- Hemophilia Treatment and Research
- Blood Coagulation and Thrombosis Mechanisms
- Hepatitis B Virus Studies
- Neonatal Respiratory Health Research
- Anesthesia and Sedative Agents
Independent University
2025
Takeda (United States)
2024
Pakistan Institute of Nuclear Science and Technology
2021
Center for Biologics Evaluation and Research
2011-2020
University of Florida
2019-2020
Columbus Oncology and Hematology Associates
2019-2020
Mid Essex Hospital Services NHS Trust
2019
Broomfield Hospital
2019
United States Food and Drug Administration
2008-2018
Institute of Space Technology
2008-2011
Abstract Tisagenlecleucel (Kymriah; Novartis Pharmaceuticals) is a CD19-directed genetically modified autologous T-cell immunotherapy. On August 30, 2017, the FDA approved tisagenlecleucel for treatment of patients up to 25 years age with B-cell precursor acute lymphoblastic leukemia (ALL) that refractory in second or later relapse. Approval was based on complete remission (CR) rate, durability CR, and minimal residual disease (MRD) <0.01% cohort 63 children young adults relapsed ALL...
Aims In recent years with the advent of paediatric exclusivity and requirements to conduct clinical studies in children, current emphasis is find a safe efficacious dose drug children. It has been suggested that one can predict clearance children according equation: CL child = adult × (weight child/70) 0.75 . Considering controversy surrounding exponent for prediction lack any systematic evaluation aforementioned proposal, objectives study were as follows: (i) determine if indeed most...
In recent years, with the advent of pediatric exclusivity and requirements for conducting clinical studies involving children, emphasis has been placed on finding safe efficacious doses drugs children. It suggested that one can predict clearance (CL) a drug in children according to this equation: CL child = Adult * (Weight child/70)0.75. light controversy surrounding exponent 0.75 prediction clearance, objectives study were as follows: (1) develop allometric equations based body weight or...
Speech Recognition is a technology enabling human interaction with machines. The design of speech recognition system capable 100% accuracy far from solved. This paper describes an isolated word, speaker dependent recognizing spoken words at sufficiently high accuracy. has been tested and verified on MATLAB as well the TMS320 C6713 DSK overall exceeding 90%. shows memory efficiency offered by using detection for separating silence improved performance achieved Dynamic Time Warping while...
Abstract The objective of this study was to compare the predictive performance an allometric model with that a physiologically based pharmacokinetic (PBPK) predict clearance or area under concentration‐time curve (AUC) drugs in subjects from neonates adolescents. From literature, 10 studies were identified which AUC adolescents predicted by PBPK models. In these published studies, given children either intravenous oral route. age‐dependent exponent (ADE) for prediction across age groups....
Objectives: To compare the mean reduction in bilirubin and duration of neonatal hyperbilirubinemia with probiotics comparison phototherapy alone for management hyperbilirubinemia. Study design: A randomized controlled trial Place study: Department Pediatrics Neonatology PAF Hospital, Islamabad from period April 20, 2024, to October 19th, 2024. Methodology: clinical was carried out including a total number 160 neonates, meeting selection criteria. They were randomly divided into two groups 80...
Aim: The objective of this study was to develop a minimal physiologically based pharmacokinetic (mPBPK) model predict area under the curve (AUC) and maximum plasma concentration (Cmax) drugs in subjects with varying degrees hepatic impairment compare mPBPK whole body PBPK model. Methods: Hepatic classification system, which is on Child-Pugh score used. In model, 4 physiological parameters [portal renal blood flow, glomerular filtration rate (GFR), liver size] 2 biochemical (albumin...
Background: In drug development, selecting the first-in-human dose is crucial. Similarly, in pediatric determining first-in-pediatric of paramount importance. Given that pharmacokinetic, safety, and efficacy a product are generally well established adults, this information can be used to select an appropriate for clinical trials. Methods: Two simple methods – Salisbury Rule allometric scaling were evaluated predicting initiate trial antituberculosis medicines. To assess predictive...
Fasting during the month of Ramadan is an obligatory religious practice for healthy adult Muslims. To complete a fast, individuals must abstain from eating, drinking, and taking medications dawn to sunset. Individuals may be exempt fasting on health grounds. However, some patients still fast fulfill their obligation, even if this means going against medical advice. Solid organ transplant recipients have follow strict fluid electrolyte requirements, which could challenging Ramadan, leading...